Search - tctmd.com

Displaying 1 - 20 of 68

Sort: Relevancy | Date

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Daily News

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

Michael O'Riordan

June 21, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Yael L. Maxwell

February 15, 2024

News Daily News

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

Todd Neale

February 14, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Michael O'Riordan

February 01, 2024

Advertisement

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Evolocumab Wins for Primary Prevention in VESALIUS-CV

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

Bempedoic Acid Gains CV Risk Reduction Indication

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content